Would Rituximab, a drug used in NMO spectrum, be helpful in secondary MS?
I believe that rituximab can be beneficial in younger patients with secondary or primary progressive MS, generally those under the age of 50 and especially those with rapid progression and/or evidence of inflammatory activity (new or enlarging T2 lesions or enhancing lesions on MRI). There are very few studies to support this approach to treatment, but many MS specialist share the same opinion from personal experience. The problem is getting it approved by insurance.
Revere (Rip) Kinkel MD
Director of the Multiple Sclerosis Program
Professor of Clinical Neurosciences
University of California San Diego